NeuroScientific Biopharmaceuticals Stock Price, News & Analysis (ASX:NSB) Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A About NeuroScientific BiopharmaceuticalsNeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. It was incorporated in 2002 and is based in Cottesloe, Australia.Read More NSB Stock News HeadlinesMay 20, 2022 | finance.yahoo.comWe're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash WiselyMay 20, 2022 | finance.yahoo.comWe Think NeuroScientific Biopharmaceuticals (ASX:NSB) Needs To Drive Business Growth CarefullySee More Headlines Receive NSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroScientific Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:NSB CUSIPN/A CIKN/A Webwww.neuroscientific.com Phone61 8 6382 1800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,070,000.00 Net Margins-21.58% Pretax MarginN/A Return on Equity-20.93% Return on Assets-11.24% Debt Debt-to-Equity RatioN/A Current Ratio8.39 Quick Ratio3.31 Sales & Book Value Annual Sales$4.95 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares144,600,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.73 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMs. Abby Macnish Niven B.Com.B.Sc., C.F.A., CFO & Company SecretaryMr. Stephen CarterChief Executive OfficerDougal ThringChief Operating OfficerKey Competitors3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAbzenaLON:ABZAView All CompetitorsInsidersStephen QuantrillBought 180,000 shares on 7/4/2023Total: $17,460.00 ($0.10/share)Paul RennieBought 240,134 shares on 6/1/2023Total: $24,013.40 ($0.10/share)Paul RennieBought 229,651 shares on 5/24/2023Total: $22,276.15 ($0.10/share)Anton UvarovBought 49,405 shares on 5/22/2023Total: $5,187.53 ($0.11/share)Paul RennieBought 320,968 shares on 5/17/2023Total: $26,640.34 ($0.08/share) This page (ASX:NSB) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroScientific Biopharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.